This is a preview of subscription content, log in via an institution to check access.
Reference
Kashiwa M, et al. Comparative Cost-effectiveness of Aflibercept and Ramucirumab in Combination with Irinotecan and Fluorouracil-based Therapy for the Second-line Treatment of Metastatic Colorectal Cancer in Japan. Clinical Therapeutics : 29 Jun 2020. Available from: URL: http://doi.org/10.1016/j.clinthera.2020.05.013
Rights and permissions
About this article
Cite this article
Add-on aflibercept or ramucirumab in CRC: modest benefits, high cost. PharmacoEcon Outcomes News 857, 4 (2020). https://doi.org/10.1007/s40274-020-6941-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-020-6941-z